Transcutaneous Electrical Acupuncture Point Stimulation Is Cardioprotective for Patients With Stable Ischemic Heart Disease

We evaluated the effects of electroacupuncture (EA) at Neiguan and Ximen on the prognosis of patients with stable ischemic heart disease. A total of 240 patients symptomatic with suspected coronary artery disease referred for coronary angiography were analyzed, and 232 patients (62.3 ± 9.1 years) with stable ischemic heart disease were included. The primary end point was major adverse cardiovascular events (MACEs), defined as a composite of recurrent angina requiring hospitalization, nonfatal acute myocardial infarction, cardiogenic death, and death from any other causes. Over a mean follow-up of 12 months, 9 patients (8.4%) in the EA treatment group and 22 patients (19.3%) in the control group occurred. Patients treated with EA had a significantly smaller risk of MACE (p = 0.021), recurrence of unstable angina (p = 0.033), and nonfatal myocardial infraction (p = 0.038) than that of those treated without EA. Kaplan-Meier analysis revealed that the EA and control groups began to separate at approximately 5 months and continued to diverge up to study termination. Moreover, multivariate Cox analysis showed that treatment with EA was associated with decreased likelihood of MACE within 12 months of follow-up. The circulating levels of cluster of differentiation 40 ligand but hypersensitive C-reactive protein were lower (166.0 ± 92.6 pg/ml vs 197.3 ± 79.2 pg/ml, p = 0.012) in the EA group than in the control group and decreased significantly (-30.6 ± 47.2 pg/ml vs -1.1 ± 50.4 pg/ml, p <0.001) after 12 months of treatment. EA is an effective treatment method for supporting patients with stable ischemic heart disease.

Feasibility analysis of TCB, hs-CRP, and UCB/ALB as outcome measures for dynamic assessment during phototherapy of neonates with Hyperbilirubinemia

Hyperbilirubinemia (HY) is a common condition in neonates that requires phototherapy treatment. This study aimed to evaluate the effectiveness of transcutaneous bilirubin measurements (TCB), hypersensitive C-reactive protein (hs-CRP), and unconjugated bilirubin (UCB)/albumin (ALB) as indicators of HY during neonatal phototherapy. A research group of 67 neonates with pathological HY and a control group of 55 healthy neonates were selected from a hospital between June 2020 and May 2021. TCB, hs-CRP, and UCB/ALB tests were performed before, during (at 3 days of treatment), and after (at 6 days of treatment) phototherapy in the research group and at admission in the control group. The study also included a 1-year prognostic follow-up on the research group. The study observed the difference in TCB, hs-CRP, and UCB/ALB test results between both groups and their assessment effect on adverse reactions, treatment effects, and poor prognosis in phototherapy. TCB, hs-CRP, and UCB/ALB levels were higher in the research group than in the control group and gradually decreased during phototherapy (P < 0.05). The combined TCB, hs-CRP, and UCB/ALB assay had 100.0% sensitivity and 64.58% specificity (P < 0.001) for predicting adverse reactions, 88.24% sensitivity and 80.00% specificity (P < 0.001) for predicting the effect of phototherapy, and 90.91% sensitivity and 88.89% specificity (P < 0.001) for predicting poor prognosis. The combined TCB, hs-CRP, and UCB/ALB assay showed superior assessment of adverse effects, clinical outcomes, and poor prognosis in HY neonates treated with phototherapy. TCB, hs-CRP, and UCB/ALB could be used as dynamic disease assessment indicators for HY to better prevent and treat the occurrence of HY.

Study on the Mechanism of Allergic Rhinitis Based on the Expression of FIB, PCT, hs-CRP, and Th17/Treg-IL10/IL-17 Axis Balance

BACKGROUND

The pathogenesis of allergic rhinitis (AR) is ambiguous, while it is clear that various immune cells and cytokines play crucial roles in its occurrence and development.

AIM

To investigate the effect of exogenous interleukin-10 (IL-10) on the expression of fibrinogen (FIB), procalcitonin (PCT), hypersensitive C-reactive protein (hs-CRP), and Th17/Treg-IL10/IL-17 axis balance in the nasal mucosa of rats with AR.

METHOD

In this study, 48 female-specific pathogen-free Sprague-Dawley rats were randomly divided into 3 groups: blank control group, AR group, and IL-10 intervention group. The AR model was established in the AR group and IL-10 group. The rats in the control group were treated with normal saline; the rats in the AR group were given 20 μL of saline containing 50 μg of ovalbumin (OVA) every day. The rats in the IL-10 intervention group were intraperitoneally injected with 1 mL of 40 pg/kg IL-10 and provided with OVA. The IL-10 intervention group was composed of mice with AR that received IL-10. The behavior of nasal allergic symptoms (such as nasal itching, sneezing, and runny nose) and the hematoxylin and eosin staining of nasal mucosa were observed. The levels of FIB, PCT, hs-CRP, IgE, and OVA sIgE in serum were determined by enzyme-linked immunosorbent assay. The levels of Treg and Th17 cells in serum were detected by flow cytometry. The protein levels of TGF-β, IL-10, and IL-17 in nasal mucosa were detected by the Western-blot method.

RESULTS

The scores of snots, nasal itching, and sneezing in the AR group were significantly higher than those in the control group, while the scores of the above symptoms in the IL-10 intervention group were lower than those in the AR group. The levels of FIB, PCT, hs-CRP, IgE, and OVA sIgE in serum and the protein levels of IL-10 and IL-17 in the nasal mucosa in the AR group were higher than those in the blank control group. Meanwhile, the levels of FIB, PCT, hs-CRP, IgE, and OVA sIgE in serum and IL-10 and IL-17 protein in the nasal mucosa in the IL-10 group were lower than those in the AR group.

CONCLUSION

IL-10 can relieve the allergy of AR rats by affecting the expression of FIB, PCT, and hs-CRP, as well as the balance of the Th17/Treg-IL10/IL-17 axis in the nasal mucosa of AR rats.

[Diagnostic value of serum amyloid A, procalcitonin and hypersensitive C-reactive protein for pulmonary tuberculosis complicated by pneumonia]

OBJECTIVE

To assess the value of serum amyloid A (SAA), procalcitonin (PCT) and high-sensitivity C-reactive protein (hs-CRP) in the diagnosis of pulmonary tuberculosis (PTB) complicated by pneumonia.

OBJECTIVE

We collected serum samples from patients with pneumonia, patients with PTB, patients with PTB complicated by pneumonia and patients with PTB complicated by sepsis hospitalized in our hospital between April, 2019 and April, 2020. Serum levels of SAA, PCT and hs-CRP were tested, and receiver- operating characteristic (ROC) curves were used to evaluate their efficacy for predicting PTB with concurrent pneumonia and the possibility of differentiating PTB cases with pneumonia from those with sepsis using these 3 parameters. We also tested serum levels of SAA, PCT and hs-CRP in patients with PTB and those with PTB complicated by pneumonia admitted from May to July in 2020 to verify the accuracy of these 3 parameters combined for predicting the complication of PTB by pneumonia.

OBJECTIVE

Compared with the patients with PTB, the patients with pneumonia had significantly higher SAA and hs-CRP levels; serum SAA, PCT and hs-CRP levels were all significantly elevated in patients with PTB complicated by pneumonia (all P < 0.05). The levels of hs-CRP, white blood cell, D-dimer, FIB, APTT and neutrophil ratio were positively correlated with serum SAA level (all P < 0.05). The areas under the ROC curve (AUC) for serum SAA, PCT, and hs-CRP were 0.762, 0.781, and 0.800, respectively, and their combined AUC was 0.849 (all P < 0.001). For predicting PTB complicated by pneumonia, SAA combined with PCT had the same sensitivity (53.85%) and specificity (90.48%) as SAA, PCT and hs-CRP all combined. Serum SAA and PCT levels were similar between PTB patients with pneumonia and those with sepsis.

OBJECTIVE

Combined detection of serum SAA and PCT levels can be helpful in the diagnosis of PTB complicated by pneumonia, but neither of them is capable of differentiating the complication of pneumonia from sepsis possibly due to influence by abnormal blood coagulation.

Changes of cardiac troponin I and hypersensitive C-reactive protein prior to and after treatment for evaluating the early therapeutic efficacy of acute myocardial infarction treatment

The present study aimed to evaluate the utility of the extent of change (C) and change rate (Cr) of cardiac troponin I (cTnI) and hypersensitive C-reactive protein (hs-CRP) prior to and after treatment in evaluating the early therapeutic efficacy of acute myocardial infarction (AMI) treatment. A total of 145 patients with AMI who received regular MI treatment were enrolled in the present study. Patients were divided into the effective group and the ineffective group based on the early therapeutic efficacy. The values of two parameters, namely the serum levels of cTnI and hs-CRP, were collected prior to and after AMI treatment. Data were analyzed by using the t-test, Chi-squared test, logistic regression and receiver operating characteristic (ROC) curve analysis. Compared with those in the ineffective group, the values of cTnI and hs-CRP after treatment [cTnI_(post) and hs-CRP_(post)], as well as their C and Cr values, were significantly decreased in the effective group (P<0.01). Furthermore, the positive rates (PR) of cTnI_(post), hs-CRP_(post), (cTnI+hs-CRP)_(post), C_(cTnI), C_(hs-CRP) and C_{(cTnI+hs-CRP)} were significantly lower in the effective group compared with those in the ineffective group (P<0.01). It was indicated that hs-CRP_(post) and C_(hs-CRP), as well as the PR-cTnI_(post) and the PR-C_(cTnI), may be used as independent factors for early therapeutic efficacy evaluation (P<0.05). In addition, the area under the ROC curve, as well as the associated sensitivity and specificity analysis for cTnI_(post), hs-CRP_(post), C_{(cTnI or hs-CRP)} and Cr_{(cTnI or hs-CRP)}, all indicated that these parameters were able to distinguish between the effective and the ineffective groups. The present study revealed that compared with the cTnI_(post) and hs-CRP_(post), the C and the Cr of cTnI and hs-CRP may have enhanced value for evaluating the early therapeutic efficacy of AMI treatment.

Elevated Serum Matrix Metalloproteinase-9, Interleukin-6, Hypersensitive C-Reactive Protein, and Homocysteine Levels in Patients with Epilepsy

Neuroinflammation contributes to the occurrence and development of epilepsy. However, several inflammatory factors that are important for facilitating the diagnosis to reduce or prevent seizures need to be further studied. This study is aimed to explore serum levels of matrix metalloproteinase-9 (MMP-9), interleukin-6 (IL-6), hypersensitive C-reactive protein (hs-CRP), and homocysteine (HCY) in epilepsy patients and the relationship of them with epilepsy. Epilepsy patients (n = 101) in the Second Xiangya Hospital from January 2017 to August 2018 were allocated to the epilepsy groups, which were divided into idiopathic epilepsy group (n = 43) and symptomatic epilepsy group (n = 58) according to the pathogeny. Healthy individuals (n = 50) were allocated to the control group. The concentrations of serum MMP-9, IL-6, hs-CRP, and HCY in all samples were detected by enzyme-linked immunosorbent assay, chemiluminescence method, latex-enhanced immunoturbidimetry, and enzyme circulation method. The levels of serum MMP-9, IL-6, hs-CRP, and HCY in epilepsy patients were higher than those in the control group (P < 0.05, P < 0.01, P < 0.01, and P < 0.01, respectively). The levels of serum MMP-9, IL-6, hs-CRP, and HCY in the symptomatic epilepsy group were higher than those in the control group (P < 0.01 or P < 0.05, respectively). The levels of serum MMP-9, IL-6, and hs-CRP in idiopathic epilepsy patients were higher than those in the control group (P < 0.01 or P < 0.05, respectively). The serum HCY level in the idiopathic epilepsy group was lower than that in the symptomatic epilepsy group (P < 0.01). MMP-9, IL-6, hs-CRP, and HCY may be recommended as the state biomarker to distinguish etiology of epilepsy. We hope our study could provide help in some ways for clinical diagnosis and treatment.

Effects of dl-3-n-butylphthalide on serum lipoprotein-associated phospholipase A2 and hypersensitive C-reactive protein levels in acute cerebral infarction

OBJECTIVE

This study aims to explore the curative effect of dl-3-n-butylphthalide (NBP) on patients with acute cerebral infarction (ACI) and its effects on serum lipoprotein-associated phospholipase A2 (Lp-PLA2) and hypersensitive C-reactive protein (hs-CRP) levels.

METHODS

A total of 136 ACI patients treated in our hospital, who met the criteria, were selected and randomly divided into two groups: control group (n = 60, including 28 males and 32 females) and treatment group (n = 76, including 32 males and 44 females). Patients in the control group were treated with routine drug therapy, while patients in the treatment group were treated with NBP on this basis. A dose of 100 ml was administered by intravenous injection for 2 times/day, for 14 days. The curative effect was evaluated using the National Institute of Health Stroke Scale (NIHSS) and Barthel index (BI) self-care ability. The levels of the two factors in serum were measured using enzyme-linked immunosorbent assay, and the changes in levels of these two factors in serum at different time points before and after treatment were compared between the two groups.

RESULTS

(a) Lp-PLA2 and hs-CRP levels in the treatment group after treatment were significantly lower than those before treatment and those in the control group after treatment (p < .05). (b) The NIHSS and BI scores in the treatment group were significantly lower after treatment than before treatment and those in the control group after treatment (p < .05).

CONCLUSION

Dl-3-n-butylphthalide can improve the expression of Lp-PLA2 and hs-CRP in serum in ACI patients. Furthermore, NBP has significant efficacy in inhibiting inflammation and improving neurological symptoms.

Increase of the Serum FGF-23 in Ossification of the Posterior Longitudinal Ligament

STUDY DESIGN

Case-control study.

OBJECTIVES

To determine the possible pathogenesis of ossification of the posterior longitudinal ligament (OPLL) in regard to the serum concentration of fibroblast growth factor 23 (FGF-23).

METHODS

The study included 95 patients with OPLL and a control group of 73 age- and sex-matched volunteers. The serum concentrations of FGF-23, creatinine (Cre), alkaline phosphatase, calcium (Ca), inorganic phosphate (Pi), and hypersensitive C-reactive protein (hs-CRP) were analyzed from blood samples, and Cre, Ca, Pi, and tubular reabsorption of phosphate were measured using urine samples. We evaluated the severity of ossified spinal lesions in patients with OPLL according to the ossification index (the OP index and the OS index). Data was compared between the OPLL and control group and between the OPLL progression and no progression group.

RESULTS

Serum FGF-23 and hs-CRP were higher, and serum Pi was lower in patients with OPLL than in the controls. There was a positive correlation between FGF-23 and hs-CRP and a negative correlation between serum Pi and the OS index; however, the correlations were very weak. Overall, 31.7% of patients had progression of OPLL during follow-up. FGF-23 and hs-CRP were higher in the progression group than in the no progression group.

CONCLUSIONS

These results might indicate that FGF-23 and hs-CRP are positive markers for OPLL. Phosphate metabolism via FGF-23 might be a target for future study on the pathogenesis of OPLL.

Study of the Inflammatory Mechanisms in Hyperhomocysteinemia on Large-Artery Atherosclerosis Based on Hypersensitive C-Reactive Protein-A Study from Southern China

OBJECTIVE

To study the inflammatory mechanism of hyperhomocysteinemia on large-artery atherosclerosis based on hypersensitive C-reactive protein in patients.

METHODS

In all, 153 inpatients and 1357 physical examinees were selected. The levels of homocysteine were compared between the carotid/intracranial artery stenosis group and the nonstenosis group, between the carotid artery unstable plaque group and the nonplaque group, and between the intima-media thickness (IMT) greater than or equal to 1 group and the normal IMT group. The hypersensitive C-reactive protein levels were compared between the lacunar infarction (LI) group and the nonstroke control group and between the unstable plaque group and the nonplaque group.

RESULTS

Homocysteine level was significantly higher in the carotid/intracranial artery stenosis group than in the nonstenosis group, in the LI group than in the inpatient nonstroke group, and in the IMT greater than or equal to 1 group than in the normal IMT group. The hypersensitive C-reactive protein level was significantly higher in the LI group than in the nonstroke group and in the unstable plaque group than in the nonplaque group.

CONCLUSIONS

Hyperhomocysteinemia may aggravate the development of IMT, carotid atherosclerotic plaque instability, and carotid/intracranial artery stenosis by increasing inflammation, ultimately leading to the occurrence of LI. Hyperhomocysteinemia-induced inflammation mechanism warrants further study.

Von Mises Strain as a Risk Marker for Vulnerability of Carotid Plaque: Preliminary Clinical Evaluation of Cerebral Infarction

Non-invasive assessment of carotid artery plaque vulnerability is a key issue for cerebrovascular disease. This study investigates Von Mises strain imaging in patients by relating Von Mises strain to cerebral infarction presentation. Ultrasonography was performed in patients evaluated for carotid artery stenosis. Strains were estimated by a flow-driven diffusion method and least-squares regression applying Kalman filtering. Von Mises strains ɛ_VM^sys and ɛ_VM^dia were calculated by averaging four or five cardiac cycles in systole and diastole, respectively. Von Mises strain (peak, coefficient of variance, skewness and kurtosis) in patients with cerebral infarction was compared with that in the control group. Higher Von Mises peak strain localized to echolucent areas on B-mode imaging. Higher peak strain was found in patients with cerebral infarction compared with the control group (p = 0.02 for ɛ_VM^dia and p = 0.001 for ɛ_VM^sys). The area under the receiver operating characteristic curve for peak ɛ_VM^sys was 0.761 (p = 0.001) with high sensitivity and specificity. Peak strain also correlated with homocysteine (r = 0.345, p = 0.007, for ɛ_VM^dia; r = 0.287, p = 0.036, for ɛ_VM^sys) and hypersensitive C-reactive protein (r = 0.399, p = 0.043, for ɛ_VM^dia; r = 0.195, p = 0.034, for ɛ_VM^sys) levels. The coefficient of variance, skewness and kurtosis of ɛ_VM^dia or ɛ_VM^sys were also associated with homocysteine levels. In conclusion, this study indicates that peak Von Mises strain is a potential clinical risk marker for carotid plaque vulnerability and cerebral infarction.

Correlation of clinical features with hs-CRP in TRD patients

Correlation of clinical features with hypersensitive C-reactive protein (hs-CRP) in patients with treatment-resistant depression (TRD) was investigated. The severity of disease in 103 TRD patients and 103 non-TRD patients was evaluated using the Hamilton Depression Scale (HAMD)-17. The levels of hs-CRP in both groups were detected via immunofluorescence. Clinical features and differences in hs-CRP before and after treatment in both groups were analyzed, and correlation of baseline hs-CRP level with clinical features of TRD patients was also analyzed. Moreover, the relationship between hs-CRP and occurrence of TRD was analyzed using logistic regression analysis, and the diagnostic value of hs-CRP in TRD was evaluated using the receiver operating characteristic (ROC) curve. The onset age in the TRD group was lower than that in the non-TRD group, the education in the TRD group was shorter than that in the non-TRD group, the total course of disease in the TRD group was longer than that in the non-TRD group, and both baseline and post-treatment hs-CRP level in the TRD group (12.05±5.79 and 9.02±3.71 mg/l) were higher than those in the non-TRD group (7.85±2.85 and 6.10±2.74 mg/l) (p<0.05). The HAMD score (r=0.338, p=0.031), anxiety/somatization factor score (r=0.465, p=0.015) and sleep disorder (r=0.387, p=0.029) of TRD patients were positively correlated with the hs-CRP level, but the onset age (r=−0.59, p=0.009) was negatively correlated with the hs-CRP level. Logistic regression analysis revealed that the baseline hs-CRP was included into the TRD regression equation [odds ratio (OR) =2.834, 95% confidence interval (CI) =1.723–4.886], and the area under the ROC curve was 0.893 (p<0.05, 95% CI=0.852–0.933). In the TRD group, the course of TRD in patients was longer, the onset of disease was earlier and the educational level was lower than that in the non-TRD group. Therefore, the level of hs-CRP can serve as a reference for the diagnosis of TRD.

Combining Porous Magnetic Ni@C Nanospheres and CaCO3 Microcapsule as Surface-Enhanced Raman Spectroscopy Sensing Platform for Hypersensitive C-Reactive Protein Detection

In this work, we have designed an efficient and rapid surface-enhanced Raman spectroscopy (SERS) immunosensor for a supersensitive analysis of hypersensitive C-reactive protein (hs-CRP) with a label-free method by combining porous magnetic Ni@C nanospheres to aggregate together for simplifying the experiment operation and CaCO₃ microcapsule to encapsulate rhodamine B as the Raman signal. The final solution containing the signal molecule was dropped on the Ag nanoparticle substrate, and the signal could be enhanced by Ag particles. First, rhodamine B was encapsulated in the CaCO₃ microcapsule when it precipitated to form microcubes. Subsequently, the porous CaCO₃ microcapsule was assembled layer by layer with poly(ether imide) (PEI) and a second antibody to obtain rhodamine B@CaCO₃@PEI@Ab₂. Then, the functionalized magnetic Ni@C nanospheres were prepared to immobilize the primary antibody (Ab₁). Finally, the immunosensor was fabricated by the sandwiched antibody-antigen interactions. Compared to the DNA hydrogel, the low-cost CaCO₃ microcapsule would be rapidly dissolved by ethylene diamine tetraacetic acid, releasing rhodamine B to produce a strong Raman signal for a rapid and efficient detection of hs-CRP. With the hs-CRP concentration ranging from 0.1 pg mL^-1 to 1 μg mL^-1, the SERS intensity of the platform has a linear relationship with the logarithm of hs-CRP concentration, and the detection limit was 0.01 pg mL^-1. By this smart design, this work can give a direction for a rapid label-free SERS analysis.

Study on the clinical efficacy of specific phosphodiesterase inhibitor in patients with pulmonary hypertension due to left heart disease

Pulmonary hypertension due to left heart disease (PH-LHD) is caused by left ventricular (LV) systolic and/or diastolic dysfunction and left heart valve disease. LV diseases lead to left ventricular filling pressure increases, pulmonary venous obstruction and pulmonary venous pressure increases, and thus to secondary PH. Exercise tolerance is lower and fatality rates are higher in patients with PH-LHD than those in subjects with normal pulmonary arterial pressure. In spite of the progress in the study of the mechanisms of PH-LHD in recent years, no specific treatment is currently available. The efficacy and safety of targeted therapies for pulmonary arterial hypertension remain to be fully established. In the present study, PH-LHD patients were treated with milrinone injection. It was concluded that milrinone significantly reduces pulmonary artery systolic pressure (PASP) in patients with PH-LHD, and significantly improves the cardiac structure, cardiac function and biochemical indexes. PASP was significantly correlated with the left atrial diameter, LV end diastolic diameter, LV ejection fraction, tricuspid annular plane systolic excursion, right ventricular fractional area change, N-terminal pro-B-type natriuretic peptide and hypersensitive C-reactive protein.

AMPKα, hs-CRP and FcγR in diabetic nephropathy and drug intervention

The aim of this study was to investigate the roles of AMP-activated protein kinase α subunit (AMPKα), hypersensitive C-reactive protein (hs-CRP) and Fcγ receptor (FcγR) in diabetic nephropathy and drug intervention effects. Sixty Sprague Dawley male rats were randomly divided into the control (n=30) and observation (n=30) groups. The model of type 2 diabetic nephropathy was established by high-fat and high-glucose diet and streptozotocin injection. The rats in the observation group were treated with baicalein and the rats in control group did not receive any drug intervention. The pathological changes of kidneys were observed by hematoxylin and eosin (H&E) staining. The expression of AMPKα mRNA in renal tissue was detected by reverse transcription-polymerase chain reaction (RT-PCR). The levels of hs-CRP and FcγR were measured by enzyme-linked immunosorbent assay (ELISA) at 1, 4, 6 and 8 weeks after drug intervention and blood urea nitrogen (BUN) and the 24 h urinary micro-albumin (U-ALB) levels were compared at 1, 4, 6 and 8 weeks after intervention. After 8 weeks of drug intervention, the pathological changes of kidneys in the observation group were significantly lower than those in the control group (p<0.05), while the relative expression levels of AMPKα mRNA and protein in the control group were higher than those in the observation group (p<0.05). The levels of hs-CRP, BUN and 24 h U-ALB in the control group were significantly higher than those in the observation group at different time-points after drug intervention and the level of FcγR in the control group was significantly lower than that in the observation group (p<0.05). Baicalein may protect renal function by inhibiting the expression of AMPKα and inflammatory reaction, and can also decrease BUN and 24 h U-ALB levels and improve the pathological changes of the kidney.

Increased Serum C3 and Decreased UA in Patients of Bipolar Disorder in Chinese Han Population

The aim of this study is to explore the changes and clinical significance of serum C3, C4, hypersensitive C-reactive protein (hsCRP) and uric acid (UA) in patients of bipolar disorder (BD). In this case-control study, we recruited 141 BD patients from The Second Xiangya Hospital, Central South University, and 151 age and gender matched healthy controls (HC) from the health management central of The Second Xiangya Hospital. These patients were divided into two subgroups based on medicines use: 91 patients were treated with psychiatric drugs and 50 patients were drugs free, or four subgroups based on mood states: 54 patients in manic/hypomanic phase, 30 patients in depressive phase, 52 patients in euthymic phase and 5 patients in mixed phase. Serum levels of C3, C4, hsCRP and UA were measured in all subjects. The serum C3 levels in BD patients (0.9981 ± 0.1849 g/L) were significantly lower than that in HC group (1.0637 ± 0.2186 g/L), especially the drugs free subgroup and the euthymic subgroup (0.975 ± 0.153 and 0.983 ± 0.182 g/L), while the serum UA levels were significantly higher (354.6 ± 90.4 vs. 332.9 ± 88.7 μmol/L), especially the drug-treated subgroup and manic/hypomanic subgroup (361.56 ± 93.20 and 376.70 ± 88.89 μmol/L), and rates of hyperuricaemia (31.91 vs. 17.88%) were significantly higher in BD patients than in HC group. The serum C4 and hsCRP levels in HC group showed no significant difference with BD patients in whole or those subgroups. These findings suggested that the complement and purinergic systems of BD patients might be disrupted, the UA levels could be a potential marker in manic phase and the C3 might be the marker of therapeutic evaluation of BD patients.